Two undercover videos released by Project Veritas this week confirm suspicions many of us have had since the beginning of the pandemic.
There’s a plan for annual COVD vaccines — made possible in part by mandates — and the U.S. Food and Drug Administration (FDA) is making recommendations potentially harming millions of Americans because they’re funded by the pharmaceutical industry, whose products they regulate.
In the first video published on Feb. 15, FDA executive Christopher Cole exposed the FDA’s vaccine plans and what Americans can expect the pharma-funded agency to sign off on in the near future.
“Biden wants to innoculate as many people as possible, so you’ll have to get an annual shot. It hasn’t been formally announced yet cause they don’t want to, like, rile everyone up,” Cole said. “Drug companies, food companies, vaccine companies, pay us hundreds of millions of dollars a year to hire and keep reviewers to approve their products.”
If they [pharmaceutical companies] can get every person required an annual vaccine, that is a recurring return of money going into their company,” Cole said. “I mean just from everything I’ve heard they’re not going to not approve this.”
According to Project Veritas, Cole is an Executive Officer with over 20 years of experience and leads the agency’s Countermeasures Initiatives, which “plays a critical role in ensuring that drugs, vaccines and other measures to counter infectious diseases and viruses are safe.”
Cole claimed in the video to be directly involved in the approval process of COVID vaccines.
Cole said he thinks it’s going to be a gradual thing beginning with vaccine mandates in schools for children with annual boosters.
The FDA was in the news this week for canceling a meeting scheduled to review Pfizer’s request to authorize its vaccine for children under five. Cole said he “didn’t agree with the [approval] process.” He further clarified that all of the data aren’t there.
Cole went on to say the FDA is “not going to not approve the vaccine” for children aged 4 months to 5 years because even though COVID cases are low among that age group, Emergency Use Authorization can be used as a means of approving it anyway.
In a statement provided to Project Veritas, FDA press officer Abigail Capobianco said Cole does not work on vaccine matters and does not represent the views of the FDA. Yet, Project Veritas contacted Cole, who said he was not contacted by the FDA before the press officer released her statement.
Billions given to yearly FDA by companies whose products they regulate
Later in the video, Cole provided a window into what really goes on behind the FDA’s approval process:
“There’s a billion dollars a year going into the FDA’s budget from the people we regulate. If they can get every person required an annual vaccine, that is a recurring return of money going into their company.”
In a second video published by Project Veritas on Feb. 16, Cole went on to say that they [big pharma] give the agency more money, which increases the chance of approval, and said the FDA is dependent on the drug and vaccine companies for their agency to operate. Approving yearly COVID vaccines would give the FDA a “recurring fountain of revenue.”
Cole said “a long time ago,” Congress approved user fees for the FDA and those fees are feeding corruption. “Basically we charge the [Big Pharma] industry millions of dollars in order to hire more drug reviewers, which will speed up the approval process so they make more money,” Cole explained.
Cole also disclosed the FDA’s budget is about 5.5 billion dollars — with a billion dollars a year going into the agency’s budget from the people they regulate.
“[…] Drug companies, the food companies, the vaccine companies, they pay us hundreds of millions of dollars a year to hire and keep the reviewers to approve their products,” Cole said.
The FDA “whitewashes” the impact of their user fees on their operations because they know they’re dependent on the vaccine companies and these other companies for their agencies to operations,” he said. Because of this, there’s “more pressure to approve something.”
“And all these like organizations within the FDA started to see all this cash in their eyes. It’s like, ‘oh I need to grab some of that’ and I think we’ve gone too far on that,” Cole explained. “They’re getting a little overzealous charging the user fees to other non-payroll expenses.”
Congress responded by approving smaller user fees, but Cole said that didn’t really solve the problem, adding you’re not going to have a long shelf-life at the agency if you speak out and there are no protections for the whistleblowers who do.